< Terug naar vorige pagina
Onderzoeker
Thomas Morel
- Disciplines:Gastro-enterologie en hepatologie, Immunologie, Pediatrie en neonatologie, Verpleegkunde
Affiliaties
- Hepatologie (Afdeling)
Lid
Vanaf1 apr 2019 → 31 mrt 2022 - Klinische Farmacologie en Farmacotherapie (Afdeling)
Lid
Vanaf1 jul 2013 → 31 mrt 2019
Projecten
1 - 1 of 1
- Weesziekten en Weesgeneesmiddelen: wat telt voor de patiënten, hoe evolueert de markt en wat zijn de misvattingen.Vanaf1 okt 2013 → 11 jan 2019Financiering: Eigen Middelen zoals patrimonium, inschrijvingsgelden, giften, ....
Publicaties
1 - 10 van 22
- Improving Interpretation of Evidence Relating to Quality of Life in Health Technology Assessments of Rare Disease Treatments(2023)
Auteurs: Thomas Morel
Pagina's: 7 - 17 - The FATIGUE-PRO: a new patient-reported outcome instrument to quantify fatigue in patients affected by systemic lupus erythematosus(2022)
Auteurs: Thomas Morel
Pagina's: 3329 - 3340 - Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease(2021)
Auteurs: Thomas Morel
- The Patient Experience of Fatigue in Systemic Lupus Erythematosus: A Conceptual Model(2021)
Auteurs: Thomas Morel
Pagina's: 95 - 108 - Psychometric Analysis from EMBODY1 and 2 Clinical Trials to Help Select Suitable Fatigue PRO Scales for Future Systemic Lupus Erythematosus Studies(2021)
Auteurs: Thomas Morel
Pagina's: 1287 - 1301 - SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials(2021)
Auteurs: Thomas Morel
- Rare diseases and orphan drugs: patient values, market trends and misconceptions.(2019)
Auteurs: Thomas Morel, Steven Simoens, David Cassiman
- Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group(2018)
Auteurs: Thomas Morel, Steven Simoens
Pagina's: 493 - 500 - Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures(2017)
Auteurs: Thomas Morel
- Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012(2017)
Auteurs: Kim Pauwels, Isabelle Huys, Minne Casteels, Thomas Morel, Steven Simoens